Research programme: monoclonal antibody therapeutics - AVEO

Drug Profile

Research programme: monoclonal antibody therapeutics - AVEO

Alternative Names: AV-232; AV-323; AV-325; AV-353; AV-368; AV-369; AV-370; AV-371; AV-378; AV-380

Latest Information Update: 05 May 2016

Price : $50

At a glance

  • Originator St Vincents Hospital, Sydney
  • Developer AVEO Oncology
  • Class Monoclonal antibodies
  • Mechanism of Action Growth differentiation factor 15 inhibitors; Hepatocyte growth factor inhibitors; Immunomodulators; Notch signalling pathway inhibitors; Notch-3 receptor antagonists; Proto oncogene protein c met inhibitors; RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cachexia; Pulmonary arterial hypertension

Highest Development Phases

  • Preclinical Cachexia; Cancer; Pulmonary arterial hypertension

Most Recent Events

  • 02 May 2016 Preclinical trials in Pulmonary arterial hypertension in USA (unspecified route)
  • 02 May 2016 AVEO Oncology files for patent protection with the United States Patent and Trademark Office for AV 353
  • 15 Mar 2016 Aveo Pharmaceuticals has patent protection for anti-GDF15 antibodies in USA, Europe, Japan, Canada and Australia (Aveo Pharmaceuticals, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top